Custo-utilidade do tratamento primário não farmacológico do glaucoma primário de ângulo aberto no sistema público de saúde brasileiro
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
Glaucoma is a genetic and chronic disease, defined as a typical optic neuropathy that
results in functional and structural damage. Primary open-angle glaucoma is the most
prevalent type of glaucoma, and treatments aim at controlling intraocular pressure,
either by surgery, medication or laser. There are factors that can cause failure in clinical
treatment, such as drugs´ excessive cost and side effects. As a consequence of the
increase in life expectancy of the Brazilian population, the incidence of glaucoma tends
to rise significantly, generating an increase in its economic impact on the expenses of
patients, health systems and society as a whole. The objective of the study is to
evaluate the economic impact of initiating the treatment of POAG with nonpharmacological strategies within the reference centers for the treatment of glaucoma
by the SUS. Three treatment strategies were studied: the first follows the usual SUS
therapy; strategies 2 and 3 have the same treatment initiation, using SLT laser, but
what differs them is the therapeutic option after SLT. The Markov model was chosen
based on the characteristics of the pathology under study, as it is a chronic disease
with recurrent and growing costs, using the incremental cost-utility ratio (ICUR) as an
outcome measure, in which the incremental cost per benefit is achieved (R$/QALY).
Strategies 2 and 3 generated a gain in quality of life, and were dominant over strategy
1, being more effective and cheaper. However, the cost-effectiveness of strategy 2
suffers a significant impact according to the age of entry into the model. Therefore, we
conclude that when starting the treatment of initial POAG with SLT, there is a gain in
quality of life and a reduction in future costs in relation to the usual treatment with eye
drops. The use of the trabecular device after laser failure generates an even greater
gain in quality of life, and its cost, although higher, can be considered cost-effective
from the perspective of SUS.
Description
Keywords
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

